Clinical, in vivo, and in vitro studies have demonstrated that age, race, immune responses, hormones, hormone receptor expression, the epigenetic and genetic alterations all can vary between tumors from male and female bladder cancer patients (summarized in Table 1). Here, NR4A1 is linked to urinary bladder carcinoma.